Header Logo

Connection

NANCY WEIGEL to Prostatic Neoplasms

Back to Details
This is a "connection" page, showing publications NANCY WEIGEL has written about Prostatic Neoplasms.
NANCY WEIGEL
Connection Strength
5.005
Prostatic Neoplasms
  1. Cistrome and transcriptome analysis identifies unique androgen receptor (AR) and AR-V7 splice variant chromatin binding and transcriptional activities. Sci Rep. 2022 03 30; 12(1):5351.
    View in: PubMed
    Score: 0.411
  2. Androgen receptor and its splice variant, AR-V7, differentially induce mRNA splicing in prostate cancer cells. Sci Rep. 2021 01 14; 11(1):1393.
    View in: PubMed
    Score: 0.378
  3. Differential regulation of metabolic pathways by androgen receptor (AR) and its constitutively active splice variant, AR-V7, in prostate cancer cells. Oncotarget. 2015 Oct 13; 6(31):31997-2012.
    View in: PubMed
    Score: 0.263
  4. Androgen receptor and its splice variant, AR-V7, differentially regulate FOXA1 sensitive genes in LNCaP prostate cancer cells. Int J Biochem Cell Biol. 2014 Sep; 54:49-59.
    View in: PubMed
    Score: 0.241
  5. The prostate cancer TMPRSS2:ERG fusion synergizes with the vitamin D receptor (VDR) to induce CYP24A1 expression-limiting VDR signaling. Endocrinology. 2014 Sep; 155(9):3262-73.
    View in: PubMed
    Score: 0.240
  6. Targeted disruption of the p160 coactivator interface of androgen receptor (AR) selectively inhibits AR activity in both androgen-dependent and castration-resistant AR-expressing prostate cancer cells. Int J Biochem Cell Biol. 2013 Apr; 45(4):763-72.
    View in: PubMed
    Score: 0.216
  7. 1a,25-dihydroxyvitamin D3 inhibits C4-2 prostate cancer cell growth via a retinoblastoma protein (Rb)-independent G1 arrest. Prostate. 2011 Jan 01; 71(1):98-110.
    View in: PubMed
    Score: 0.189
  8. 1Alpha,25-dihydroxyvitamin D3 reduces c-Myc expression, inhibiting proliferation and causing G1 accumulation in C4-2 prostate cancer cells. Endocrinology. 2009 May; 150(5):2046-54.
    View in: PubMed
    Score: 0.165
  9. Androgen receptor coactivators and prostate cancer. Adv Exp Med Biol. 2008; 617:245-55.
    View in: PubMed
    Score: 0.153
  10. Interactions between vitamin D and androgen receptor signaling in prostate cancer cells. Nutr Rev. 2007 Aug; 65(8 Pt 2):S116-7.
    View in: PubMed
    Score: 0.149
  11. Androgens modulate expression of transcription intermediary factor 2, an androgen receptor coactivator whose expression level correlates with early biochemical recurrence in prostate cancer. Cancer Res. 2006 Nov 01; 66(21):10594-602.
    View in: PubMed
    Score: 0.141
  12. Androgen receptor action in hormone-dependent and recurrent prostate cancer. J Cell Biochem. 2006 Oct 01; 99(2):362-72.
    View in: PubMed
    Score: 0.141
  13. Androgen receptor signaling and vitamin D receptor action in prostate cancer cells. Prostate. 2005 Sep 01; 64(4):362-72.
    View in: PubMed
    Score: 0.130
  14. Role of SRC-1 in the promotion of prostate cancer cell growth and tumor progression. Cancer Res. 2005 Sep 01; 65(17):7959-67.
    View in: PubMed
    Score: 0.130
  15. Vitamin D receptor agonists induce prostatic acid phosphatase to reduce cell growth and HER-2 signaling in LNCaP-derived human prostate cancer cells. J Steroid Biochem Mol Biol. 2005 Oct; 97(1-2):37-46.
    View in: PubMed
    Score: 0.130
  16. Role of insulin-like growth factor binding proteins in 1alpha,25-dihydroxyvitamin D(3)-induced growth inhibition of human prostate cancer cells. Prostate. 2005 Jun 15; 64(1):9-19.
    View in: PubMed
    Score: 0.128
  17. 1alpha,25-dihydroxyvitamin D3 induced growth inhibition of PC-3 prostate cancer cells requires an active transforming growth factor beta signaling pathway. Prostate. 2004 May 15; 59(3):282-91.
    View in: PubMed
    Score: 0.119
  18. Vitamin D and prostate cancer. Exp Biol Med (Maywood). 2004 Apr; 229(4):277-84.
    View in: PubMed
    Score: 0.118
  19. Stable expression of full length human androgen receptor in PC-3 prostate cancer cells enhances sensitivity to retinoic acid but not to 1alpha,25-dihydroxyvitamin D3. Prostate. 2003 Sep 01; 56(4):293-304.
    View in: PubMed
    Score: 0.113
  20. p53 Is required for 1,25-dihydroxyvitamin D3-induced G0 arrest but is not required for G1 accumulation or apoptosis of LNCaP prostate cancer cells. Endocrinology. 2003 Jan; 144(1):50-60.
    View in: PubMed
    Score: 0.108
  21. A novel androgen receptor mutant, A748T, exhibits hormone concentration-dependent defects in nuclear accumulation and activity despite normal hormone-binding affinity. Mol Endocrinol. 2002 Dec; 16(12):2692-705.
    View in: PubMed
    Score: 0.108
  22. Uridine Diphosphate Glucuronosyl Transferase 2B28 (UGT2B28) Promotes Tumor Progression and Is Elevated in African American Prostate Cancer Patients. Cells. 2022 07 29; 11(15).
    View in: PubMed
    Score: 0.105
  23. Vitamin D and prostate cancer. J Androl. 2002 Jan-Feb; 23(1):9-17.
    View in: PubMed
    Score: 0.101
  24. A calcitriol analogue, EB1089, inhibits the growth of LNCaP tumors in nude mice. Cancer Res. 2000 Feb 15; 60(4):779-82.
    View in: PubMed
    Score: 0.089
  25. A C619Y mutation in the human androgen receptor causes inactivation and mislocalization of the receptor with concomitant sequestration of SRC-1 (steroid receptor coactivator 1) Mol Endocrinol. 1999 Dec; 13(12):2065-75.
    View in: PubMed
    Score: 0.087
  26. Vitamin D and prostate cancer. Proc Soc Exp Biol Med. 1999 Jun; 221(2):89-98.
    View in: PubMed
    Score: 0.085
  27. Inositol polyphosphate 4-phosphatase type II regulation of androgen receptor activity. Oncogene. 2019 02; 38(7):1121-1135.
    View in: PubMed
    Score: 0.081
  28. 1,25-dihydroxyvitamin D3 and 9-cis-retinoic acid act synergistically to inhibit the growth of LNCaP prostate cells and cause accumulation of cells in G1. Endocrinology. 1997 Apr; 138(4):1491-7.
    View in: PubMed
    Score: 0.073
  29. Nuclear Receptor Corepressor 1 Expression and Output Declines with Prostate Cancer Progression. Clin Cancer Res. 2016 08 01; 22(15):3937-49.
    View in: PubMed
    Score: 0.068
  30. Metabolomic profiling identifies biochemical pathways associated with castration-resistant prostate cancer. J Proteome Res. 2014 Feb 07; 13(2):1088-100.
    View in: PubMed
    Score: 0.058
  31. Potent activity of the Hsp90 inhibitor ganetespib in prostate cancer cells irrespective of androgen receptor status or variant receptor expression. Int J Oncol. 2013 Jan; 42(1):35-43.
    View in: PubMed
    Score: 0.054
  32. Decreased expression and androgen regulation of the tumor suppressor gene INPP4B in prostate cancer. Cancer Res. 2011 Jan 15; 71(2):572-82.
    View in: PubMed
    Score: 0.047
  33. EB1089 inhibits the parathyroid hormone-related protein-enhanced bone metastasis and xenograft growth of human prostate cancer cells. Mol Cancer Ther. 2009 Jul; 8(7):1787-98.
    View in: PubMed
    Score: 0.043
  34. Parathyroid hormone-related protein regulates cell survival pathways via integrin alpha6beta4-mediated activation of phosphatidylinositol 3-kinase/Akt signaling. Mol Cancer Res. 2009 Jul; 7(7):1119-31.
    View in: PubMed
    Score: 0.043
  35. Coactivator selective regulation of androgen receptor activity. Steroids. 2009 Aug; 74(8):669-74.
    View in: PubMed
    Score: 0.042
  36. Target gene-specific regulation of androgen receptor activity by p42/p44 mitogen-activated protein kinase. Mol Endocrinol. 2008 Nov; 22(11):2420-32.
    View in: PubMed
    Score: 0.040
  37. Prostate cancer cell type-specific involvement of the VDR and RXR in regulation of the human PTHrP gene via a negative VDRE. Steroids. 2006 Feb; 71(2):102-15.
    View in: PubMed
    Score: 0.033
  38. Inhibition of proliferation and induction of apoptosis by 25-hydroxyvitamin D3-3beta-(2)-Bromoacetate, a nontoxic and vitamin D receptor-alkylating analog of 25-hydroxyvitamin D3 in prostate cancer cells. Clin Cancer Res. 2004 Dec 01; 10(23):8018-27.
    View in: PubMed
    Score: 0.031
  39. Regulation of Bcl-2 expression by dihydrotestosterone in hormone sensitive LNCaP-FGC prostate cancer cells. J Urol. 2003 Apr; 169(4):1553-7.
    View in: PubMed
    Score: 0.028
  40. Molecular analysis of the androgen receptor in ten prostate cancer specimens obtained before and after androgen ablation. J Androl. 2003 Mar-Apr; 24(2):215-25.
    View in: PubMed
    Score: 0.027
  41. Novel nonsecosteroidal vitamin D receptor modulator inhibits the growth of LNCaP xenograft tumors in athymic mice without increased serum calcium. Prostate. 2001 Nov 01; 49(3):224-33.
    View in: PubMed
    Score: 0.025
  42. Use of the probasin promoter ARR2PB to express Bax in androgen receptor-positive prostate cancer cells. J Natl Cancer Inst. 2001 Sep 05; 93(17):1314-24.
    View in: PubMed
    Score: 0.025
  43. Androgen receptor mutations in prostate cancer. Cancer Res. 2000 Feb 15; 60(4):944-9.
    View in: PubMed
    Score: 0.022
  44. Calcitriol-induced apoptosis in LNCaP cells is blocked by overexpression of Bcl-2. Endocrinology. 2000 Jan; 141(1):10-7.
    View in: PubMed
    Score: 0.022
  45. Androgen receptors and their biology. Vitam Horm. 2001; 62:199-230.
    View in: PubMed
    Score: 0.006
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.